+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

E

Actively Recruiting

Psoriatic arthritis PsA is a chronic inflammatory condition affecting the joints and skin of people with psoriasis PsO. This research aims to evaluate how well the drug zasocitinib works in adults with active PsA who have not previously been treated with biologic disease-modifying antirheumatic drugs. The study is a phase 3 trial comparing zasocitinib to an active comparator and placebo to assess treatment effects and safety. Participants are randomly assigned to one of four groups. One group receives zasocitinib Dose A orally once daily for up to 52 weeks, another group receives zasocitinib Dose B once daily for the same period, a third group receives the active comparator capsules twice daily for up to 52 weeks, and the fourth group receives placebo once daily for 16 weeks followed by zasocitinib Dose A or B from Week 16 to Week 52. This design allows comparison between different doses, placebo, and active treatments. During the study, participants will be monitored regularly with evaluations including joint assessments and skin lesion checks. Researchers will measure responses such as improvement in arthritis symptoms using the American College of Rheumatology 20 ACR20 response at Week 16 as the primary outcome. Secondary measures include skin improvement and various quality of life and disease activity scores. The study duration for participants is up to 60 weeks, including treatment and follow-up, to assess both efficacy and safety of the treatments.

Age: 18Years +All GendersPhase 3
188 locations
E

Actively Recruiting

Researchers are studying targeted therapies for adults with moderately to severely active Rheumatoid Arthritis RA, a chronic condition causing joint pain, stiffness, swelling, and loss of function. This Phase 2 trial aims to evaluate the safety and effectiveness of three different treatment approaches compared to placebo in participants who have not responded well to one or two prior biologic or targeted synthetic disease-modifying antirheumatic drugs btsDMARDs. The study includes three substudies Lutikizumab monotherapy versus placebo, Ravagalimab monotherapy versus placebo, and a combination of Lutikizumab and Ravagalimab versus placebo. Treatments are given as subcutaneous injections with participants randomized to receive either active drugs or matching placebo doses. Approximately 180 participants will enroll and receive study treatments during the trial. Participants will have regular visits at hospitals or clinics where medical assessments, blood tests, side effect monitoring, and questionnaires will be conducted. The main outcomes measured include the percentage of participants achieving significant improvement in RA symptoms American College of Rheumatology 50% response at 12 weeks and tracking adverse events up to about 22 weeks. The study continues until November 2027 with ongoing safety and efficacy monitoring.

Age: 18Years +All GendersPhase 2
96 locations
A

Actively Recruiting

Researchers are evaluating bimekizumab administered intravenously compared to subcutaneous injection in adults with active psoriatic arthritis or active axial spondyloarthritis. The study aims to show that the intravenous method is not less effective than the subcutaneous method by assessing how the drug moves in the body over time. This is a Phase 1, open-label, randomized, parallel-group study focused on treatment. Participants will receive one of three dosing regimens of bimekizumab during a pharmacokinetics lead-in phase and continue with the same assigned regimen during the treatment period. The dosing regimens include intravenous and subcutaneous administration of bimekizumab at specified times. Subjects are randomized into one of two experimental arms reflecting different intravenous regimens or a third arm receiving the subcutaneous regimen. During the study, participants will be monitored for steady-state trough concentration of the drug at week 16. Safety is assessed by tracking treatment-emergent adverse events, serious adverse events, and any events leading to withdrawal from the study through week 29. The study duration extends to the end of safety follow-up, with regular assessments to evaluate drug levels and participant health under medical supervision.

Age: 18Years +All GendersPhase 1
63 locations
S

Actively Recruiting

Researchers are evaluating KBP-336, a drug designed to treat knee pain caused by osteoarthritis in people who are also living with obesity. This Phase 2 clinical trial aims to find out if KBP-336 can reduce pain and body weight compared to a placebo, while also assessing its effects on quality of life, metabolism, and safety. The study is sponsored by KeyBioscience AG and focuses on adults aged 45 years and older with diagnosed osteoarthritis of the knee and obesity. Participants in this study will receive weekly subcutaneous injections of KBP-336 or a placebo for six months. The study compares multiple dosages of KBP-336 against placebo, with participants visiting the clinic every two weeks for checkups and tests. Throughout the trial, participants will maintain a diary recording their symptoms and use of any additional pain medications allowed as rescue treatment. During the study, participants will be regularly assessed using several tools, including the Western Ontario and McMaster Universities Osteoarthritis Index WOMAC for pain, stiffness, and function, as well as quality of life questionnaires AQol 8D. Researchers will monitor changes in body weight, pain levels, body composition, bone density, and medication use over 183 days. Safety and well-being will be closely observed through physical exams, vital signs, ECGs, and lab tests, with the total trial duration lasting about six months for each participant.

Age: 45Years +All GendersPhase 2
20 locations
E

Actively Recruiting

Researchers are evaluating sarilumab, given at two different doses, for treating adults aged 50 years and older with early polymyalgia rheumatica PMR. This randomized, double-blind, placebo-controlled Phase 3 study aims to compare the effectiveness of sarilumab plus a 52-week prednisone taper against placebo plus the same prednisone taper. The purpose is to assess whether sarilumab can improve sustained remission rates and to determine its safety and tolerability in this population. Participants are assigned to one of three groups placebo with prednisone taper, sarilumab 150 mg every two weeks with prednisone taper, or sarilumab 200 mg every two weeks with prednisone taper. The prednisone taper lasts 52 weeks. The study includes an initial screening visit, baseline and randomization visit with first drug administration, multiple treatment visits every two weeks from Week 2 to Week 44, an end of treatment visit at Week 52, and a final study visit at Week 58. During the study, participants will undergo regular assessments including monitoring for remission status, flare rates, and changes in PMR activity scores. Safety will be evaluated by tracking adverse events, laboratory values, and antibody formation against the drug throughout the study period up to Week 58. Participants may also complete quality of life questionnaires during the study. The total participation time spans approximately 58 weeks.

Age: 50Years +All GendersPhase 3
85 locations
P

Actively Recruiting

Researchers are evaluating targeted therapies for adult participants with active psoriatic arthritis, a condition where the immune system attacks healthy cells causing joint pain, stiffness, and swelling. This phase 2 study aims to assess the effectiveness and safety of risankizumab and lutikizumab, either alone or combined, in improving disease symptoms. The trial will include about 120 participants worldwide and focuses on measuring changes in disease activity and side effects. Participants will be randomly assigned to one of three treatment groups risankizumab alone, lutikizumab alone with doses every other week, or a combination of both drugs following the monotherapy dosing schedules. All treatments are given by subcutaneous injection. The study includes regular visits to clinics or hospitals where treatments are administered and monitored. During the study, participants will undergo medical evaluations including joint assessments, blood tests, and questionnaires to track symptoms and side effects. The main outcomes measured include the percentage of participants achieving a 50% improvement in arthritis symptoms by week 16 and the number of adverse events up to week 52. Participants will attend scheduled visits throughout the study, and safety will be closely monitored until the study ends in 2028.

Age: 18Years +All GendersPhase 2
37 locations